The competition for glucose between tumors and T cells may modulate the function of immune cells and influence cancer progression.[67] Combined therapy with PD‐1 and CTLA4 promoted T cell glycolysis, thereby restricting tumor cells’ access to enough glucose.[67] Thus, the synergistic effect of Siglec‐G and PD‐1 may further enhance glycolysis in T cells, altering the metabolic pressure in the nutrient‐deficient TME. Here, CTLA4 is linked to cancer.